04:19 PM EDT, 03/23/2026 (MT Newswires) -- Apogee Therapeutics ( APGE ) said Monday it has started an underwritten public offering of $300 million of shares, subject to market conditions.

Apogee said it expects to give underwriters a 30-day option to buy up to an additional $45 million of shares.

The company said it will use net proceeds, together with cash, cash equivalents, marketable securities and long-term marketable securities, to fund preclinical studies, clinical trials, and other projects, as well as working capital and general corporate purposes.